
|Articles|June 25, 2007
New form of existing wake-promoting drug approved
The FDA has given the go-ahead to Cephalon Inc. to market armodafinil (Nuvigil) for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift-work sleep disorder.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Shows Improvements in Blood Sugar, Cardiovascular Risk Factors
2
Q&A: Fentanyl, Opiophobia Concurrently Contribute to Ongoing Opioid Crisis
3
Expansion of OTC Contraceptive Could Fill Reproductive Health Disparities
4
Pharmacists Provide Tailored Pneumococcal Vaccines to Patients With Down Syndrome
5




















































































































































